LifeVantage (NASDAQ:LFVN - Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, May 2nd. Parties interested in registering for the company's conference call can do so using this link.
LifeVantage (NASDAQ:LFVN - Get Free Report) last posted its earnings results on Tuesday, January 30th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $51.62 million for the quarter. LifeVantage had a return on equity of 19.96% and a net margin of 1.40%.
LifeVantage Trading Up 1.1 %
Shares of NASDAQ LFVN traded up $0.07 during mid-day trading on Thursday, hitting $6.24. The company had a trading volume of 5,015 shares, compared to its average volume of 34,324. The stock's 50-day moving average price is $6.59 and its 200-day moving average price is $6.42. The company has a market capitalization of $80.31 million, a price-to-earnings ratio of 26.83 and a beta of 0.78. LifeVantage has a 1 year low of $3.04 and a 1 year high of $8.69.
About LifeVantage
(
Get Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Featured Articles
Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
